for stability in the HTS buffer. Experimental procedures were identical to those used in Figure S7 . 
Redox-activity Redox-activity
Compound (+) DTT (−) DTT Compound (+) DTT (−) DTT 1a − − 6o − − 2a − − 6p − − 3a − − 6q − − 4a − − 6r − − 6a + + 6s − + 6b + + 6t − + 6c + + 6u − − 6d − − 6w − − 6e − + 6y + + 6f + − 7a − − 6h + + 7b − − 6i − + 7c − − 6j + + 7d − − 6k + + NSC-663284 + − 6l + + 4-amino-1-naphthol + + 6m − + Fluconazole − − 6n + +
Asf1
None − − − a Score derived from the p-value that indicates the statistical significance of the peptide-spectrum match. Good quality score > 25 -45; high quality score > 45 1 .
Table S3 | Compound-peptide adducts detected by protein mass spectrometry.
Compounds 1a, 6a and 6b were incubated with yeast Rtt109, Vps75 or Asf1. CPM was included as a positive thiol-reactive control compound. Representative, high-confidence peptide adducts are provided. Support for detection of compound-peptide adducts from tandem MS data is based on: (1) very high confidence in the peptide sequence from fragment ions that support at least five consecutive b-or y-type fragment ions; (2) expected mass accuracy for precursor m/z (< 7 ppm); and (3) key peaks that support site localization of cysteine modification on amino acid fragments. a Structure annotations: A, any atom; ns, number of substituents (e.g. "2s"); nr number of connected ring bonds (e.g. "2r"); X, halogen. b Ndata designates the subset of compounds for which a pBSF score had been derived. This is dependent on the availability of HTS screening data. c Expected incidence of anomalous binders is 6% (averaged over all compounds). Table S5 | Published examples of compounds containing chemotype 6 that are unlikely to be selective chemical probes.
CHEMICAL SYNTHESES AND CHARACTERIZATION

General description
The 1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded on a Bruker Avance spectrometer. The 13 C NMR (176 MHz) spectra were recorded on a Bruker Avance III 700-MHz spectrometer with a 1.7-mm TCI Cryoprobe. Chemical shifts are reported in ppm using the solvent peak as an internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triple, q = quartet, m = multiplet), coupling constant, and integration.
Samples were analyzed for purity using a Waters Acquity UPLC system equipped with a BEH C18 2.1 x 50 mm column. The flow rate was 0.250 mL/min with a standard gradient starting at 95% Solution A (950 mL H 2 O, 50 mL MeCN, 1 mL formic acid) and ending with 100% Solution B (1000 mL MeCN plus 1 mL formic acid) over 6.5 min. The samples were monitored simultaneously using an ELS detector, a diode array detector (214, 220, 244 and 254 nm) and a ZQ mass spectrometer (ESI positive and negative ion modes). Low-resolution mass spectra (LRMS) were recorded using this ZQ mass spectrometer.
High-resolution mass spectra (HRMS) were recorded as previously described 6 5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl) 4-((4-Bromophenyl)sulfonamido)-1-hydroxynaphthalen-2-yl) N-(3-((1H-1,2,4-Triazol-3-yl)thio)-4-hydroxynaphthalen-1-yl) 1-(4-bromophenyl) 
Screening compound characterization
4-(5-((1,1-Dioxidobenzo[b]thiophen-3-yl)thio)-1H-tetrazol-1-yl)benzoic acid (1a
1-(4-Bromophenyl)-3-((
3-((
Compound-GSH adduct syntheses and characterization
-2,5-dioxopyrrolidin-3-yl)thio)-1-((carboxymethyl)amino)-1oxopropan-2-yl)-L-glutamine
(4a'). 1-(4-bromophenyl)-3-((5-(2-hydroxyphenyl)-1,3,4oxadiazol-2-yl)thio)pyrrolidine-2,5-dione 4a (1 mg, 2.241 µmol) was dissolved in MeCN (0.2 mL) and HTS buffer (4.5 mL). This mixture was shaken at 30 °C for 5 min, then GSH (1.4 mg, 4.56 µmol) was added. The reaction was shaken at 30 °C and monitored by UPLC-MS until starting material was consumed. The crude reaction analyzed by LC-HRMS for the titled compound 4a': rt = 8.98 min. HRMS (ES+) m/z calculated for C 20 -((R)-1-((Carboxymethyl)amino)-3-((1,4-dioxo-1,4-dihydronaphthalen-2-yl) (1H-1,2,4 -triazol-3-yl)thio)-4-hydroxynaphthalen-1yl)naphthalene-2-sulfonamide 6b (2.9 mg, 6.47 µmol) was dissolved in MeCN (2.3 mL), H 2 O (3 mL), and HTS buffer (5 mL). This mixture was shaken at 30 °C for 5 min, then GSH (4 mg, 13 µmol) was added. The reaction was shaken at 30 °C and monitored by UPLC-MS until starting material was consumed. The crude reaction analyzed by LC-HRMS for the titled compound 6'':
Examples of interference compounds reported in the scientific literature
Based on straightforward SciFinder searches, there are many examples of the problematic chemotypes described in this study (1, 2, 3, 4, 6 and 7) found in the scientific literature. Specifically, this includes benzothiophene 1,1-dioxides 7-9 , p-hydroxyarylsulfonamides 2-5, 10-24 , 1,2,4-thiadiazoles 25-44 , 3-arylsulfonyl-succinimides 45, 46 and benzothiadiazoles/benzofurazans [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . Some of these manuscripts only report compounds containing these chemotypes as being active in an HTS setting and make no further claims. Others, unfortunately, make rather dubious claims about the biological utility and specificity for these frequent-hitting interference compounds.
